Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discounts will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Biological Chemistry
Vertex Pharmaceuticals will pay Ribometrix $20 million to develop up to three RNA-targeted small-molecule treatments. The partners are not identifying drug targets, but Ribometrix previously disclosed to C&EN that it is pursuing molecules that bind to messenger RNA related to the cancer driver c-Myc and that target mRNA connected with the protein implicated in Huntington’s disease. Ribometrix was founded in 2017 based on discoveries of chemist Kevin Weeks at the University of North Carolina at Chapel Hill.
This article has been sent to the following recipient: